Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | RXRA | P19793 | 2/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3474325 | 0.91 | RXRA (0.51) | MAPTSMN1; SMN2TP53POLBRXRA | |
| SCHEMBL3471938 | 0.90 | ORAI1 (0.60) | MAPTSMN1; SMN2TP53POLBRXRA | |
| SCHEMBL3471277 | 0.90 | MAPT (0.57) | MAPTSMN1; SMN2TP53POLBRXRA | |
| SCHEMBL3471324 | 0.90 | MAPT (0.59) | MAPTSMN1; SMN2TP53POLBRXRA | |
| SCHEMBL3474142 | 0.89 | MAPT (0.59) | MAPTSMN1; SMN2TP53POLBRXRA | |
| SCHEMBL3472102 | 0.89 | MAPT (0.61) | MAPTSMN1; SMN2TP53POLBRXRA | |
| SCHEMBL3471118 | 0.88 | MAPT (0.57) | MAPTSMN1; SMN2TP53POLBRXRA | |
| SCHEMBL3473738 | 0.88 | PTGS2 (0.57) | MAPTSMN1; SMN2TP53POLBRXRA | |
| SCHEMBL3472857 | 0.88 | MAPT (0.57) | MAPTSMN1; SMN2TP53POLBRXRA | |
| SCHEMBL3474338 | 0.88 | MAPT (0.50) | MAPTSMN1; SMN2TP53POLBRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | MAPT 4737/4885SMN1; SMN2 4666/4885TP53 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.